Medical and recreational cannabis markets continue to have a growing impact on the broader U.S. economy, but the state-level impact differs based on each market’s size, maturity and type.
Hemp plantings in the United States were nearly cut in half in 2022, with 28,400 acres dedicated to growing the plant – slightly more than the acreage set aside for Christmas trees.
It’s been a little more than a year since New Mexico launched adult-use marijuana, with sales topping $300 million during the initial 12 months.
The total U.S. economic impact generated by marijuana sales is expected to top $100 billion in 2023, up more than 12% from last year, according to a fresh analysis from the newly published MJBiz Factbook.
The MJBizDaily editorial team is gearing up to produce its 11th annual MJBiz Factbook, and we would like your input.
In the spirit of “a picture is worth 1,000 words,” here are charts and maps that visualize a few of the cannabis industry trends that MJBizDaily saw in 2022.
Populous urban areas once again provided a majority of the voters supporting marijuana legalization ballot initiatives during the November midterm elections, according to an analysis of state election results.
The percentage of executive positions held by women and racial minorities in the U.S. cannabis industry remained little changed in 2022 compared to last year, according to a new report from MJBizDaily.
Unlike 2020, the marijuana industry appears less likely to record a clean sweep of victories when residents in five states head to the polls during this year’s midterm elections to vote on adult-use legalization ballot initiatives.
Election results for 2022 marijuana-related ballot initiatives in Arkansas, Maryland, Missouri, North Dakota, and South Dakota.
If the Florida medical marijuana market were a race, all bets would be on Trulieve Cannabis.
The largest CBD companies in the U.S. experienced declining market share in the second quarter, as the return of in-person shopping triggered a decline in e-commerce sales.
Market share by revenue for the top 20 CBD brands shrank 2 percentage points, to 16%, versus the first quarter of the year, according to Chicago-based cannabis analytics firm Brightfield Group.
